Measles Encephalitis: Towards New Therapeutics

Area of Science:

• Virology
• Neurology
• Immunology

Background:

• Measles virus (MeV) is a significant global health threat, causing morbidity and mortality, particularly due to vaccine-preventable disease resurgence.
• MeV infection can lead to severe central nervous system (CNS) complications, including acute post-infectious measles encephalitis (APME), sub-acute sclerosing panencephalitis (SSPE), and measles inclusion-body encephalitis (MIBE).
• The mechanisms of MeV CNS invasion and spread remain poorly understood, as known MeV entry receptors are not typically expressed in the brain.

Purpose of the Study:

• To review the current understanding of measles virus neural infection.
• To discuss advanced therapeutic approaches for treating MeV-induced CNS manifestations.
• To highlight the challenges and future directions in managing measles neurological complications.

Main Methods:

• Literature review of scientific articles on measles virus, CNS infections, and antiviral therapies.
• Analysis of studies detailing MeV pathogenesis in the central nervous system.
• Synthesis of data on in vitro, ex vivo, and in vivo antiviral treatment efficacy.

Main Results:

• MeV can cause direct CNS infection (SSPE, MIBE) or indirect neurological damage (APME).
• Existing antiviral treatments show promise in preventing infection but require further evaluation for efficacy after CNS manifestations.
• Understanding MeV entry and spread in the brain is crucial for developing targeted therapies.

Conclusions:

• Effective management of measles CNS infections requires a deeper understanding of viral neuroinvasion.
• Further research is needed to evaluate and develop antiviral strategies specifically for established MeV neurological disease.
• Improved vaccination coverage remains critical to prevent measles and its devastating neurological sequelae.